Chemiluminescence method for the determination of piroxicam by the enhancement of the tris-(4,7-diphenyl-1,10-phenanthrolinedisulphonic acid) ruthenium(II) (RuBPS)-cerium(IV) system and its application

被引:6
作者
Yu, Fengshan [2 ]
Zhang, Yangbin [3 ]
Chen, Fang [2 ]
Chen, Lanhua [1 ]
机构
[1] Huaibei Coal Ind Teachers Coll, Dept Chem, Huaibei 235000, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Chem, Hubei Key Lab Bioinorgan Chem & Mat Med, Wuhan 430074, Peoples R China
[3] Liji High Sch Suining, Dept Chem, Xuzhou 221221, Peoples R China
基金
中国国家自然科学基金;
关键词
chemiluminescence; tris-(4,7-diphenyl-1,10-phenanthrolinedisulphonic acid) ruthenium(II); cerium(IV); piroxicam; PHARMACEUTICAL FORMULATIONS; ELECTROGENERATED CHEMILUMINESCENCE; QUANTITATIVE-DETERMINATION; LIQUID-CHROMATOGRAPHY; LC DETERMINATION; HUMAN PLASMA; TENOXICAM; OXIDATION; PHASE;
D O I
10.1002/bio.1063
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple, rapid chemiluminescence (CL) method was described for the determination of piroxicam, a commonly used analgesic agent drug. A strong CL signal was detected when cerium(IV) sulphate was injected into tris-(4,7-diphenyl-1,10-phenanthrolinedisulphonic acid) ruthenium(II) (RuBPS)-piroxicam solution. The CL signal was proportional to the concentration of piroxicam in the range 2.8 x 10(-8)-1.2 x 10(-5) mol/L. The detection limit was 2 x 10(-8) mol/L and the relative standard deviation (RSD) was 3.7% (c = 7.0 x 10(-7) mol/L piroxicam; n = 11). The proposed method was applied to the determination of piroxicam in pharmaceutical preparations in capsules, spiked serum and urine samples with satisfactory results. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:50 / 54
页数:5
相关论文
共 30 条
[1]   Electrochemical monitoring of piroxicam in different pharmaceutical forms with multi-walled carbon nanotubes paste electrode [J].
Abbaspour, Abdolkarim ;
Mirzajani, Roya .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 44 (01) :41-48
[2]   Determination of piroxicam in pharmaceutical formulations and urine samples using europium-sensitized luminescence [J].
Al-Kindy, Salma M. Z. ;
Suliman, Fakhr Eldin O. ;
Al-Wishahi, Aisha A. ;
Al-Lawati, Haidar A. J. ;
Aoudia, Muhammed .
JOURNAL OF LUMINESCENCE, 2007, 127 (02) :291-296
[3]   Rapid method for the determination of piroxicam in rat plasma using high-performance liquid chromatography [J].
Amanlou, M ;
Dehpour, AR .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1997, 696 (02) :317-319
[4]   Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin [J].
Amin, AS .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (04) :729-736
[5]   Two different strategies for the fluorimetric determination of piroxicam in serum [J].
Arancibia, JA ;
Escandar, GM .
TALANTA, 2003, 60 (06) :1113-1121
[6]   Post-chemiluminescence phenomenon of NBS-Luminol reactions and their applications to flow injection analysis of piroxicam [J].
Bai, Hao ;
Nie, Fei ;
Lu, Jiuru .
ANALYTICAL SCIENCES, 2007, 23 (11) :1301-1304
[7]   Spectrofluorimetric determination of 2-aminopyridine as a potential impurity in piroxicam and tenoxicam within the pharmacopoeial limit [J].
Barary, MH ;
Abdel-Hay, MH ;
Sabry, SM ;
Belal, TS .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 34 (01) :221-226
[8]   Quantitative determination of piroxicam in a new formulation (piroxicam-β-cyclodextrin) by derivative UV spectrophotometric method and HPLC [J].
Basan, H ;
Göger, NG ;
Ertas, N ;
Orbey, MT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2001, 26 (02) :171-178
[9]   Electrogenerated chemiluminescence using solution phase and immobilized tris(4,7-diphenyl-1,10-phenanthrolinedisulfonic acid)ruthenium(II) [J].
Blanchard, RM ;
Martin, AF ;
Nieman, TA ;
Guerrero, DJ ;
Ferraris, JP .
MIKROCHIMICA ACTA, 1998, 130 (1-2) :55-62
[10]   Quantitative determination of Piroxicam by TLC-MALDI TOF MS [J].
Crecelius, A ;
Clench, MR ;
Richards, DS ;
Parr, V .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 35 (01) :31-39